{"title":"Analysis of clinical characteristics in 1940 patients with acute pulmonary embolism.","authors":"Bo Chen, Wei Wang, Wenqian Zang, Jinjin Hu, Hengyun Li, Cong Wang, Yingwei Zhu, Yimin Mao, Pengfei Gao","doi":"10.1016/j.rmed.2024.107920","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The clinical characteristics of acute pulmonary embolism (APE) according to mortality risk has been partly explored. Further research is required in light of the latest guide update on risk stratification for APE.</p><p><strong>Methods: </strong>We collected the data from hospitalized patients with APE. Patients were classified according to the 2019 European Society of Cardiology's (ESC) guidelines. The clinical traits between different risk stratification of APE was investigated.</p><p><strong>Results: </strong>A total of 1940 patients had APE. Patients who were stratified as high risk showed the highest frequency of both syncope (4.5 % vs 6.6 % vs 12.7 %; P = 0.002) and dyspnea (61.9 % vs 73.0 % vs 73.8 %, P = 0.007) when compared to the other two groups. The rates of deep venous thrombosis (DVT) were: 49.4 % in low-risk stratification, 63.2 % in intermediate-risk stratification, and 68.1 % in high-risk stratification, (P<sub>for trend</sub> = 0.001), while the proportion of low-risk stratification patients increased (2.5 %-13.3 %, P<sub>for trend</sub><0.001).</p><p><strong>Conclusion: </strong>In conclusion, clinical characteristics differ among pulmonary embolism patients with different risk stratification. Furthermore, the percentage of low-risk patients increased progressively while overall in-hospital death rates among APE patients gradually decreased.</p>","PeriodicalId":21057,"journal":{"name":"Respiratory medicine","volume":" ","pages":"107920"},"PeriodicalIF":3.5000,"publicationDate":"2024-12-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Respiratory medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.rmed.2024.107920","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The clinical characteristics of acute pulmonary embolism (APE) according to mortality risk has been partly explored. Further research is required in light of the latest guide update on risk stratification for APE.
Methods: We collected the data from hospitalized patients with APE. Patients were classified according to the 2019 European Society of Cardiology's (ESC) guidelines. The clinical traits between different risk stratification of APE was investigated.
Results: A total of 1940 patients had APE. Patients who were stratified as high risk showed the highest frequency of both syncope (4.5 % vs 6.6 % vs 12.7 %; P = 0.002) and dyspnea (61.9 % vs 73.0 % vs 73.8 %, P = 0.007) when compared to the other two groups. The rates of deep venous thrombosis (DVT) were: 49.4 % in low-risk stratification, 63.2 % in intermediate-risk stratification, and 68.1 % in high-risk stratification, (Pfor trend = 0.001), while the proportion of low-risk stratification patients increased (2.5 %-13.3 %, Pfor trend<0.001).
Conclusion: In conclusion, clinical characteristics differ among pulmonary embolism patients with different risk stratification. Furthermore, the percentage of low-risk patients increased progressively while overall in-hospital death rates among APE patients gradually decreased.
背景:急性肺栓塞(APE)的临床特征与死亡风险的关系已得到部分探讨。根据最新的APE风险分层指南,需要进一步的研究。方法:收集APE住院患者的资料。根据2019年欧洲心脏病学会(ESC)指南对患者进行分类。探讨不同危险分层间的临床特征。结果:共有1940例患者发生APE。高危组患者出现两种晕厥的频率最高(4.5% vs 6.6% vs 12.7%;P=0.002)和呼吸困难(61.9% vs 73.0% vs 73.8%, P=0.007)。深静脉血栓(DVT)发生率:低危分层49.4%,中危分层63.2%,高危分层68.1% (p趋势=0.001),低危分层患者比例增加(2.5% ~ 13.3%,p趋势)。结论:不同危险分层肺栓塞患者的临床特征存在差异。此外,低风险患者的比例逐渐增加,而APE患者的总体住院死亡率逐渐下降。
期刊介绍:
Respiratory Medicine is an internationally-renowned journal devoted to the rapid publication of clinically-relevant respiratory medicine research. It combines cutting-edge original research with state-of-the-art reviews dealing with all aspects of respiratory diseases and therapeutic interventions. Topics include adult and paediatric medicine, epidemiology, immunology and cell biology, physiology, occupational disorders, and the role of allergens and pollutants.
Respiratory Medicine is increasingly the journal of choice for publication of phased trial work, commenting on effectiveness, dosage and methods of action.